Abstracts tagged "Qualitative Research"

Abstract Number: 1605 • ACR Convergence 2020
Knowledge of Biosimilars and Perceptions of Biosimilar Naming Conventions in Clinical Practice
Criswell Lavery¹, Marianna Olave², Charles Leonard¹, Vincent Lo Re¹, Jonathan Kay³ and Joshua Baker¹, ¹University of Pennsylvania, Philadelphia, PA, ²Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ³University of Massachusetts Medical School, Worcester, MA
Background/Purpose: The market introduction of biosimilars has generated the need for novel biologic naming conventions, in part to support pharmacovigilance. We evaluated the familiarity of…
Abstract Number: 1619 • ACR Convergence 2020
Immunoglobulin G Subclass Ordering Patterns for IgG4-Related Disease at an Academic Medical Center
Lena Eder¹ and David Leverenz², ¹Duke University Hospital, Chapel Hill, NC, ²Duke University, DURHAM, NC
Background/Purpose: We have noticed an increasing number of serum IgG4 levels ordered over the last several years at our institution. This study was performed to…
Abstract Number: 1666 • ACR Convergence 2020
Elucidating Research Priorities in Childhood-Onset Systemic Lupus Erythematosus: A Qualitative Study
Laura Cannon¹, Anne Skelley-Caliendo², Aimee Hersh³ and Andrea Knight⁴, ¹Duke University, Durham, NC, ²Northwestern University, Chicago, IL, ³University of Utah and Primary Children's Hospital, Salt Lake City, ⁴Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: An estimated 15 to 20% of patients with systemic lupus erythematosus (SLE) have childhood-onset SLE (cSLE). Given the early onset of cSLE, patients often…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].